Naval Daver

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Patrick Williams, Sreyashi Basu, Guillermo Garcia‐Manero et al. · Cancer · 2018 · 331 citations · Full text

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Elias Jabbour, Nicholas J. Short, Farhad Ravandi et al. · The Lancet Haematology · 2018 · 263 citations · Full text

Hematological Malignancy, First-line Therapy, Oncology +8

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

Koji Sasaki, Elias Jabbour, Farhad Ravandi et al. · Cancer · 2016 · 195 citations · Full text

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

Rita Assi, Hagop M. Kantarjian, Nicholas J. Short et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 159 citations

Tyrosine Kinase Inhibitor, Hematological Malignancy, Oncology +7

Lenalidomide promotes the development of <i>TP53</i>-mutated therapy-related myeloid neoplasms

Adam S. Sperling, Veronica Guerra, James A. Kennedy et al. · Blood · 2022 · 128 citations · Full text

Hematological Malignancy, Tumor Biology, Therapy-related Myeloid Neoplasms +13